Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 719
- Registration Number
- NCT02831673
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Fundación Huésped
- Target Recruit Count
- 145
- Registration Number
- NCT02770508
- Locations
- 🇦🇷
Fundacion huesped, Caba, Buenos Aires, Argentina
🇦🇷Centro de Estudios Infectologicos SA (CTD Stamboulian), Caba, Buenos Aires, Argentina
🇦🇷Consultorio Infectológico Dr. Pryluka, Caba, Buenos Aires, Argentina
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT02738931
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Antiretroviral Regime for Viral Eradication in Newborns
- Conditions
- HIV/AIDS and Infections
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- National Center for Women and Children's Health, China CDC
- Target Recruit Count
- 600
- Registration Number
- NCT02712801
- Locations
- 🇨🇳
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 45
- Registration Number
- NCT02652793
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
- Conditions
- HIV-1Central Nervous System
- Interventions
- Drug: ATRIPLA^TMDrug: Placebo to ATRIPLA™Drug: Placebo to Doravirine, Tenofovir, Lamivudine
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 86
- Registration Number
- NCT02652260
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT02634073
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 167
- Registration Number
- NCT02616783
- Locations
- 🇫🇷
Hopital Necker les Enfants Malades, Paris, France
🇧🇪University Hospital Gent, Ghent, Belgium
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers
- Conditions
- HIV INFECTIONS
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Universidade Federal de Pernambuco
- Target Recruit Count
- 28
- Registration Number
- NCT02604004
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 255
- Registration Number
- NCT02598063
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.